Argent Biopharma Limited ASX Delisting Update

RNS Number : 2047F

Argent Biopharma Limited

23 September 2024

 

 

23 September 2024

 

Argent BioPharma Ltd.

(Argent BioPharma or the Company)

 

Delisting Update

 

Argent BioPharma, an innovative multidisciplinary drug discovery company within the biopharmaceutical sector, provides the following update regarding its proposed delisting from the Australian Securities Exchange (ASX).

 

The Company wishes to remind shareholders that it will be holding a shareholder vote at 4:00 PM (AWST) on Tuesday, 1 October 2024, at Suite 1, 295 Rokeby Road, Subiaco WA 6008 to allow shareholders to vote (amongst other things) on its proposed delisting from the ASX. Any proposed delisting from the ASX is conditional on, amongst other things, shareholder approval.

 

To remain eligible to be listed on the London Stock Exchange's Main Market and the Financial Conduct Authority's (FCA) Official List in the event of a delisting from the ASX, application must be made to, and approved by, the FCA to transfer the Company's listing category on the Official List in accordance with the UK Listing Rules (Application). The Company is currently listed on the equity shares (international commercial companies secondary listing) category of the FCA's Official List, but prior to any delisting from ASX, the Company intends to apply to move its listing to the equity shares (commercial companies) category (ESCC) of the FCA's Official List. There are a number of prerequisites and eligibility requirements that will need to be met for an Application to be approved, one being the appointment of a Sponsor, and following any such transfer the Company would be subject to additional disclosure and corporate governance obligations. There can be no guarantee whether or when an Application to transfer listing category will be approved, in which case there is no guarantee that the Company will delist from the ASX, notwithstanding whether shareholder approval is given. The Company will not delist from the ASX without such approval of the Application to transfer to the ESCC.

 

 

-Ends-

 

 

Authorised for release by the board of directors, for further information please contact:

 

Argent BioPharma Roby Zomer CEO & Managing Director [phone] [e-mail]

Argent BioPharma Rowan Harland Company Secretary [phone] [e-mail]

 

 

About Argent BioPharma

 

Argent BioPharma Limited (the "Company") (ASX: RGT; LSE: RGT; OTCQB: RGTLF) an innovative multidisciplinary drug development Company within the biopharmaceutical sector.  The Company focuses on multidisciplinary methods with Nanotechnology, developing multi-target therapies for comprehensive disease management, especially concerning the central nervous system ("CNS") and Immunology treatments.

 

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 

END

 

 

UPDUOUNRSAUKURR